



17 June 2015, Melbourne, Australia: Circadian Technologies (ASX:CIR) has featured in CommSec's *Executive Series*. The Series interviews leading CEOs from ASX-listed companies and is hosted by Tom Piotrowski, a high profile market analyst.

Released this week, the interview is distributed internally in CommSec's Weekly wrap-up to over 50,000 clients as well as uploaded to the CommSec website and YouTube channel CommSecTV.

To view the interview, please click on the link:

www.youtube.com/watch?v=WJxMvoJErMU&feature=youtu.be

Company & Media Enquiries:

Megan Baldwin, PhD
CEO & Managing Director
Circadian Technologies Limited
Tel: +61 (0) 3 9826 0399
megan.baldwin@circadian.com.au

Rudi Michelson
Monsoon Communications
Tel: +61 (0) 9620 3333

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399
info@circadian.com.au
www.circadian.com.au

About Circadian Technologies Limited

Circadian (ASX:CIR; OTCQX:CKDXY) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C, VEGF-D and VEGFR-3. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian's internal product development programs are primarily focused on developing OPT-302 (formerly VGX-300, soluble VEGFR-3) for 'back of the eye' disease such as wet age-related macular degeneration (wet AMD). Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including IMC-3C5, a monoclonal antibody targeting VEGFR-3.